Compassionate use is the administration of an experimental medicinal product outside the legal framework provided by a clinical trial. The European Medicines Agency (EMA) provides recommendations through the Committee for Medicinal Products for Human Use (CHMP), but these do not create a legal framework.

Compassionate use programmes are coordinated and implemented by Member States, which set their own rules and procedures.